MarketCapExport financials
Phreesia (PHR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Phreesia Income Statement 2026-2011 | PHR
Brief overview of financial results at Phreesia
This overview is based on financial performance over the past five years. According to figures from Phreesia, revenue changed from 149 million dollars to 481 million dollars over five years. Across the full period, sales moved by +223.2%; the average annual rate was 26.4%. The company expanded its revenue base at a high speed.
The gross result shifted from $125 million to $409 million, or +226.8%. The relationship between sales and direct costs improved over the period. At the margin level, the figure shifted from 84.2% to 85.2%. Gross profitability remained broadly stable.
EBITDA changed from −9.8 million dollars to 24.8 million dollars (+354.4%). Additional revenue translated efficiently into EBITDA. The EBITDA share of revenue changed from −6.6% to 5.2%. Higher profitability strengthens the quality of operating growth.
The final result was −27.3 million dollars initially and 2.3 million dollars in the final year. The company restored profitability by the end of the period.
Market capitalization changed from 1.6 billion dollars to 501 million dollars (−69.6%). Capitalization lags the underlying business improvement.
Conclusion
Positive developments coexist with areas of weakness. The constructive conclusion rests on a stronger final result, higher operating efficiency and revenue expansion. Caution is warranted because of declining capitalization. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Phreesia
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
501 M | 483 M | 1.87 B | 1.77 B | 1.68 B | 1.65 B | 630 M | - | - | - | - | - | - | - | - | - |
Shares |
59.7 M | 57.6 M | 54.6 M | 52.4 M | 49.9 M | 39.5 M | 20.3 M | - | - | - | - | - | - | - | - | - |
Historical Prices |
8.38 | 8.38 | 34.2 | 33.7 | 33.7 | 41.7 | 54.3 | 26.6 | - | - | - | - | - | - | - | - |
Net Income |
2.31 M | -58.5 M | -137 M | -176 M | -118 M | -27.3 M | -20.3 M | -15.1 M | -18.2 M | - | - | - | - | - | - | - |
Revenue |
481 M | 420 M | 356 M | 281 M | 213 M | 149 M | 125 M | 99.9 M | 79.8 M | - | - | - | - | - | - | - |
Cost of Revenue |
71.4 M | 66.2 M | 61 M | 58.9 M | 42.7 M | 23.5 M | 16.8 M | 15.1 M | 12.6 M | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | 80.1 M | 62.9 M | 50.1 M | - | - | - | - | - | - | - |
Operating Income |
-6.61 M | -58.1 M | -136 M | -177 M | -117 M | -25.7 M | -15.3 M | -9.49 M | -14.6 M | - | - | - | - | - | - | - |
Interest Expense |
2.95 M | 1.96 M | 1.85 M | 1.41 M | 1.16 M | 1.7 M | 3.04 M | 3.51 M | 602 K | - | - | - | - | - | - | - |
EBITDA |
24.8 M | -30.2 M | -107 M | -151 M | -95.5 M | -9.76 M | -1.37 M | 2.1 M | -4.91 M | - | - | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | - | 95.4 M | 72.4 M | 64.6 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
79.9 M | 76.6 M | 79.9 M | 80.4 M | 68.7 M | 40.5 M | 30.5 M | 20.1 M | 18.8 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Phreesia
| 2027-Q2 | 2027-Q1 | 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
59.6 M | 60.9 M | - | 60 M | 59.6 M | 58.9 M | - | 57.9 M | 59.6 M | 58.9 M | - | 57.9 M | 57.5 M | 56.7 M | - | 55.3 M | 53.8 M | 53.3 M | - | 52.6 M | 52.3 M | 51.9 M | 44.9 M | 51 M | 50.6 M | 45.4 M | 36.6 M | 38.5 M | 37.7 M | 37.3 M | 1.99 M | 35.8 M | 6.79 M | 2.01 M | - | 1.91 M | 1.78 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-3.91 M | 2.96 M | - | 4.27 M | 654 K | -3.91 M | - | -14.4 M | 654 K | -3.91 M | - | -14.4 M | -18 M | -19.7 M | - | -31.9 M | -36.8 M | -37.5 M | - | -40.2 M | -46.7 M | -51.2 M | - | -36.3 M | -24.4 M | -11 M | -3.67 M | -6.71 M | -6.37 M | -6.11 M | -5.08 M | -2.44 M | -7.49 M | -6.7 M | - | -4.17 M | -2.59 M | -3.22 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
117 M | 131 M | - | 120 M | 117 M | 116 M | - | 107 M | 117 M | 116 M | - | 107 M | 102 M | 101 M | - | 91.6 M | 85.8 M | 83.8 M | - | 73.1 M | 67.9 M | 63.4 M | - | 55.9 M | 51 M | 20 K | 32.8 M | 4 K | 2 K | 92 K | 26.5 M | 338 K | 36 K | 28.3 M | - | 24.8 M | 24.8 M | 23.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
17.4 M | 17.7 M | - | 18.3 M | 17.4 M | 16.6 M | - | 17.9 M | 17.4 M | 16.6 M | - | 17.9 M | 16.1 M | 15.7 M | - | 15.5 M | 14.4 M | 14.9 M | - | 14.6 M | 14.9 M | 14.4 M | - | 11.6 M | 10 M | 8.53 M | - | 6.47 M | 5.27 M | 4.73 M | - | 4.39 M | 4.21 M | 4 M | - | 3.8 M | 3.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-1.51 M | 6.75 M | - | 3.74 M | -1.51 M | -3.29 M | - | -13.8 M | -1.51 M | -3.29 M | - | -13.8 M | -17.2 M | -19.4 M | - | -32 M | -37 M | -37.9 M | - | -39.8 M | -46.3 M | -50.6 M | - | -35.7 M | -23.8 M | -10.7 M | -4.67 M | -6.11 M | -6.31 M | -4.97 M | -3.3 M | -2.23 M | -4.14 M | -4.26 M | - | -3.04 M | -1.25 M | -1.91 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
336 K | -7 K | - | 1.01 M | 336 K | 338 K | - | -144 K | 336 K | 338 K | - | -144 K | -86 K | -31 K | - | -47 K | 420 K | -42 K | - | 456 K | 292 K | 402 K | - | 331 K | 226 K | 258 K | - | 471 K | 421 K | 412 K | - | 557 K | 781 K | -1.14 M | - | 203 K | 139 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-636 K | 16.7 M | - | 11.2 M | 5.9 M | 3.59 M | - | -6.76 M | 5.9 M | 3.59 M | - | -6.76 M | -9.92 M | -12.7 M | - | -24.6 M | -32.7 M | -30.9 M | - | -34.9 M | -42.1 M | -44.7 M | - | -20.3 M | -13.6 M | -5.7 M | -4.67 M | 5.54 M | 1.35 M | -1.34 M | -3.3 M | 8.04 M | 2.65 M | -881 K | - | -1.07 M | 528 K | -1.91 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
19 M | 18.4 M | - | 17.5 M | 19 M | 16.4 M | - | 19.6 M | 19 M | 16.4 M | - | 19.6 M | 19.5 M | 19.1 M | - | 20.2 M | 21 M | 19.9 M | - | 19.6 M | 20.1 M | 20.9 M | - | 18 M | 16.2 M | 12.7 M | - | 10.4 M | 9.63 M | 8.72 M | - | 7.18 M | 7.42 M | 6.24 M | - | 4.54 M | 4.65 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Phreesia (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B |  USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 9.34 | -1.37 % | $ 173 M | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
10x Genomics
TXG
|
$ 62.88 | -3.34 % | $ 7.84 B | USA |
 |
Veeva Systems
VEEV
|
$ 306.1 | -0.1 % | $ 50.1 B | USA |
 |
SCWorx Corp.
WORX
|
$ 1.31 | -5.76 % | $ 9.53 M | USA |
 |
Zhongchao
ZCMD
|
$ 0.94 | -5.99 % | $ 3.21 M |  China |
 |
HealthStream
HSTM
|
$ 28.69 | -0.14 % | $ 861 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
So-Young International
SY
|
$ 2.0 | 0.5 % | $ 156 M | China |
 |
American Well Corporation
AMWL
|
$ 12.0 | -3.73 % | $ 193 M | USA |
 |
Evolent Health
EVH
|
$ 4.79 | 1.7 % | $ 547 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.54 | -3.01 % | $ 1.26 B | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.46 | -3.31 % | $ 102 M | USA |
 |
HealthEquity
HQY
|
$ 103.68 | 1.53 % | $ 8.93 B | USA |
 |
Omnicell
OMCL
|
$ 35.87 | -3.96 % | $ 1.65 B | USA |
 |
Progyny
PGNY
|
$ 36.44 | 1.35 % | $ 3.11 B | USA |
 |
Schrödinger
SDGR
|
$ 32.42 | -2.89 % | $ 2.38 B | USA |
 |
Teladoc Health
TDOC
|
$ 8.96 | -0.28 % | $ 1.58 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |